Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Normal Drug Tolerance Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

NCT00964366
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin and benzoyl peroxide, Dapsone gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects of Single Oral Dose of 600mg TR-701

NCT00671359
View directory record Official record
Conditions
Healthy
Interventions
TR-701 600mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 2, 2026, 10:17 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

NCT00815607
View directory record Official record
Conditions
Melanoma
Interventions
INXN-1001, INXN-3001
Drug · Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Newark, Delaware • Savannah, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

NCT00712114
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 10:17 AM EDT
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
65 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
73
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

NCT00710333
View directory record Official record
Conditions
Keloid
Interventions
Avotermin, placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients

NCT03310099
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Obesity
Interventions
Increasing daily unsaturated fatty acid consumption
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

NCT00752973
View directory record Official record
Conditions
Pediculosis
Interventions
MALG (malathion) Treatment
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 24 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Bentonville, Arkansas • Jonesboro, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

NCT00001114
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2b, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 10:17 AM EDT
Not yet recruiting Not applicable Interventional

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD

NCT07440797
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Saline solution, Vashe solution
Device
Lead sponsor
Laboratoires URGO
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study Evaluating the Efficacy and Tolerability of a Topical Facial Treatment For Facial Rejuvenation

NCT06629792
View directory record Official record
Conditions
Fine Lines, Wrinkles, Laxity; Skin
Interventions
Gentle Cleanser, Facial Moisturizer, sunscreen SPF 30
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311
View directory record Official record
Conditions
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions
AZD 1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 2, 2026, 10:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Colesevelam HCl On Bile Acid Kinetics

NCT00476710
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Colesevelam HCl
Drug
Lead sponsor
KineMed
Industry
Eligibility
40 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 2, 2026, 10:17 AM EDT
Not listed Not applicable Interventional

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

NCT05276258
View directory record Official record
Conditions
Pain, Pain, Postoperative
Interventions
cryoSPHERE Ablation, Bupivacaine
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 2, 2026, 10:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 2, 2026, 10:17 AM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

NCT00291057
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 24 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2013 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 2, 2026, 10:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

NCT06442293
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
Treatment 1, Treatment 2, Placebo
Dietary Supplement
Lead sponsor
USANA Health Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation

NCT01660321
View directory record Official record
Conditions
Pediculosis
Interventions
spinosad
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months to 4 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Hot Springs, Arkansas • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Not applicable Interventional Results available

Alternating Pressure Overlay on Weight Bearing Tissue Tolerance in People With Spinal Cord Injury

NCT03317288
View directory record Official record
Conditions
Spinal Cord Injuries, Pressure Ulcer
Interventions
Dabir Air overlay
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction

NCT00982033
View directory record Official record
Conditions
Heart Failure
Interventions
aliskiren, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 2, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tolerance and Pharmacokinetics Study of MNTX Tablets

NCT01366339
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Oral methylnaltrexone, Oral placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 2, 2026, 10:17 AM EDT